Viridian Preparing To Launch Its First Drug And A Fast Follower In TED
Viridian is poised for significant activity in 2026 with an anticipated FDA approval for its first drug and multiple clinical trial readouts. The company is focusing on developing treatments for Thyroid Eye Disease (TED) and has other FcRn programs expected to yield Phase I data. This strategic outlook positions Viridian for growth in the biopharmaceutical sector.
Viridian Preparing To Launch Its First Drug And A Fast Follower In TED
Viridian is preparing for an important year in 2026, with expectations of FDA approval for its first drug and multiple clinical trial readouts, including two FcRn programs. The company aims to launch a drug for Thyroid Eye Disease (TED) and has a fast follower in the same therapeutic area, positioning itself strongly in the ophthalmology market. This comes as a rival, Argenx, experienced a setback with its Vvygart drug in TED.
Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday
Viridian Therapeutics (NASDAQ:VRDN) is expected to report its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting a loss of ($0.88) per share. The company currently holds a "Moderate Buy" consensus rating with an average price target of $42.64. Recent insider trading activity includes a sale of shares by Jennifer Tousignant, and various institutional investors have adjusted their holdings in VRDN.
Viridian Therapeutics surveys impact of thyroid eye disease on daily life
Viridian Therapeutics conducted a survey with 45 individuals living with thyroid eye disease (TED) to understand the daily impact of changes in vision and self-confidence. The initiative aims to use patient experiences to guide the company's future work in addressing challenges associated with TED.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages
Viridian Therapeutics (NASDAQ:VRDN) has received an average "Moderate Buy" rating from fifteen research firms, with an average one-year target price of $42.64. Major institutional investors like Morgan Stanley and Vanguard Group have significantly increased their stakes in the company. Viridian is a clinical-stage biopharmaceutical company focusing on antibody therapeutics, with lead programs targeting thyroid eye disease and complement-mediated pathways for autoimmune and inflammatory diseases.
How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing
This article analyzes Viridian Therapeutics Inc. (VRDN) stock, highlighting a weak near and mid-term sentiment but a strong long-term outlook. It identifies a significant short setup opportunity with an exceptional risk-reward ratio and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis suggests that despite current weak sentiment, VRDN has strong long-term potential, as indicated by multi-timeframe signal analysis.
VRDN: Needham Reiterates Buy Rating with Maintained Price Target
Needham analyst Serge Belanger has reiterated a Buy rating for Viridian Therapeutics (VRDN) and maintained a $42.00 price target. This consistent positive outlook reflects confidence in VRDN's market position and growth potential. Other analysts have also provided varying ratings and price targets, contributing to a consensus "Outperform" status, with an average target price of $40.24, implying a 26.13% upside from its current price.
Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock
Wells Fargo & Company raised its price target for Viridian Therapeutics (NASDAQ:VRDN) to $29.00 from $26.00, maintaining an "equal weight" rating, though this implies a potential downside of 12.65% from its previous close. Despite a significant revenue beat in its last earnings report, the company remains unprofitable with a negative net margin. Institutional investors increased their positions in VRDN during Q4, while an insider sold shares.
Viridian Therapeutics (VRDN) Stock Analysis: Exploring a Promising 26% Upside with Strong Buy Ratings
Viridian Therapeutics (NASDAQ: VRDN) is a biotechnology company with a market capitalization of $3.17 billion, showing strong growth potential and favorable analyst ratings. The stock is nearing its 52-week high, driven by an impressive revenue growth rate, and analysts project a potential upside of 26.15% with an average target price of $41.88. The company's pipeline includes veligrotug in Phase 3 trials for thyroid eye disease and VRDN-003 for autoimmune diseases, backing the high buy ratings despite current negative EPS.
Y Intercept Hong Kong Ltd Buys 52,414 Shares of Viridian Therapeutics, Inc. $VRDN
Y Intercept Hong Kong Ltd significantly increased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 430.3% in the third quarter, acquiring an additional 52,414 shares to now own 64,594 shares valued at $1.39 million. This move comes as Viridian Therapeutics beat Q3 earnings estimates with an EPS of ($0.34) and substantial revenue growth, though it maintains a negative net margin. Wall Street analysts largely rate the stock a "Moderate Buy" with a consensus price target of $42.43, even as one insider recently sold shares.
Evercore ISI raises Viridian Therapeutics stock price target on subQ TED potential
Evercore ISI has increased its price target for Viridian Therapeutics (NASDAQ:VRDN) to $45.00 from $44.00, maintaining an Outperform rating, based on the potential of its subcutaneous TED data expected in Q1 2026. The firm anticipates significant market share capture for Viridian's subQ product in the estimated $2 billion IGF-1R market, projecting potential peak sales of $1.4 billion worldwide and profitability by 2027. This positive outlook is supported by Viridian's strong financial position and other recent favorable analyst ratings and FDA priority review for its veligrotug treatment.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Viridian Therapeutics (NASDAQ:VRDN) has received a "Moderate Buy" consensus rating from brokerages, with 13 out of 15 analysts recommending a buy. The company recently reported a significant beat on quarterly earnings and revenue, though it remains unprofitable. Institutional interest is growing, with several large investors increasing their stakes in VRDN.
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Business Is Trailing The Industry But Its Shares Aren't
Viridian Therapeutics (NASDAQ:VRDN) has a high price-to-sales (P/S) ratio of 44.8x, significantly above the biotech industry average. Despite strong past revenue growth, analysts project the company's future revenue growth at 105% per year, which is materially lower than the broader industry's forecast of 126% per year. This suggests that the current high P/S ratio may not be sustainable, as investors appear to be hoping for a turnaround not supported by analyst expectations.
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative?
Viridian Therapeutics recently received FDA Priority Review for its thyroid eye disease drug veligrotug, setting a target decision date of June 30, 2026, and is also progressing a European filing alongside phase 3 trials for elegrobart (VRDN-003). This regulatory advancement enhances the company's thyroid eye disease franchise, bringing its potential commercialization into sharper focus. Despite recent share price strength, the investment narrative still involves execution risks regarding launch and a rich sales multiple for the currently loss-making company, with upcoming elegrobart readouts defining future competitiveness and financing needs.
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative?
Viridian Therapeutics has received FDA Priority Review for its thyroid eye disease drug veligrotug, with a decision expected by June 30, 2026, while also advancing elegrobart in Europe. This significantly progresses the company's thyroid eye disease franchise. The accelerated regulatory timeline could impact Viridian’s investment narrative, spotlighting both the potential for market reshape and increased execution risks regarding pricing and market uptake.
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN
SG Americas Securities LLC significantly increased its holdings in Viridian Therapeutics (NASDAQ:VRDN) by 411.8%, acquiring an additional 49,981 shares to bring its total to 62,118 shares worth approximately $1.34 million. This comes after Viridian Therapeutics reported an earnings beat and substantial revenue growth. Insider trading also showed Director Fairmount Funds Management LLC making a large purchase, while analysts generally rate the stock a "Moderate Buy" with an average target price of $42.31.
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com
Viridian Therapeutics Inc. (VRDN) stock has surged to a 52-week high of $34.06, reflecting an 89.7% increase over the past year and strong investor confidence. The company's Biologics License Application for veligrotug, a treatment for Thyroid Eye Disease, has been accepted for priority review by the FDA with a target action date of June 30, 2026. Analysts maintain a bullish outlook on the stock, with price targets up to $50, although the current price is slightly above InvestingPro's Fair Value estimate.
Viridian Therapeutics stock hits 52-week high at $34.06
Viridian Therapeutics (VRDN) stock reached a 52-week high of $34.06, reflecting an 89.7% increase over the past year. This surge follows the FDA's acceptance of its Biologics License Application for veligrotug for priority review, with a target action date of June 30, 2026. Analysts from UBS, TD Cowen, Jefferies, and Truist Securities have maintained or initiated "Buy" ratings, citing strong investor confidence and the company's progress.
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Viridian Therapeutics shares surged to a new 52-week high after the FDA granted Priority Review for its thyroid eye disease drug, veligrotug, with a PDUFA date of June 30, 2026. The company also anticipates pivotal Phase 3 results for elegrobart (VRDN-003) in Q1 and Q2 2026, and plans to submit a European marketing application for veligrotug in Q1. Despite competition, Viridian expects its current plans to be funded through profitability, and significant trading attention is focused on the upcoming FDA decision.
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week High - Still a Buy?
Viridian Therapeutics (NASDAQ:VRDN) recently hit a new 52-week high of approximately $34.08, with analysts assigning a consensus "Moderate Buy" rating and an average price target of $42.31. Despite beating Q1 EPS and revenue estimates significantly, the company remains unprofitable. Insider buying, including a substantial purchase by Fairmount Funds Management, and increased institutional investment, indicate strong investor confidence in VRDN.
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com
Viridian Therapeutics Inc. (VRDN) stock reached a 52-week high of $34.06, reflecting an 89.7% appreciation over the past year and an 86.6% gain in the last six months. This surge is fueled by strong investor confidence and the FDA's acceptance of its Biologics License Application for veligrotug for priority review. Analysts from UBS, TD Cowen, Jefferies, and Truist Securities maintain bullish ratings with price targets up to $50.
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug
Viridian Therapeutics (VRDN) is under investor scrutiny after the FDA granted Priority Review for its Biologics License Application for veligrotug, a drug for thyroid eye disease. Despite recent share price momentum, the company's Price-to-Sales ratio of 40.9x suggests it is overvalued compared to the biotech industry average and its estimated fair ratio. However, a Discounted Cash Flow model indicates a fair value significantly higher than the current trading price, suggesting the market might be underestimating its long-term potential.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Viridian Therapeutics announced that its Compensation Committee approved inducement grants of non-qualified stock options to purchase 16,650 shares of common stock for one new employee on January 2, 2026. These grants, made outside the company's existing equity incentive plan, are intended to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over a four-year period, tied to continued employment.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics announced that its Compensation Committee approved inducement grants of non-qualified stock options for 16,650 shares of common stock to one new employee on January 2, 2026. These grants, made under Nasdaq Listing Rule 5635(c)(4), are material to the employee's new employment and will vest over four years. The company is focused on developing best-in-class medicines for serious and rare diseases, including treatments for thyroid eye disease and autoimmune diseases.
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug
Viridian Therapeutics (VRDN) is under scrutiny after the FDA granted Priority Review for its Biologics License Application for veligrotug. Despite recent share price gains, the company's valuation appears stretched due to a high Price-to-Sales ratio compared to the biotech industry average, although a DCF model suggests a significant undervaluation. Investors are advised to consider execution risks and the company's net loss.
VRDN: Truist Securities Lowers Price Target but Maintains Buy Rating
Truist Securities has reiterated its Buy rating for Viridian Therapeutics (VRDN) but slightly lowered its price target from $41.00 to $40.00. This adjustment comes amidst various analyst ratings, with the average target price from 16 analysts suggesting a 29.71% upside from the current price. Viridian Therapeutics, a biopharmaceutical company specializing in thyroid eye disease treatments, also shows an "Outperform" status based on analyst consensus, and a significantly higher GF Value estimate from GuruFocus.
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation
UBS has initiated coverage of Viridian Therapeutics (VRDN) with a Buy recommendation. The average one-year price target suggests a 28.87% upside from its current closing price. Institutional ownership shows a slight decrease in the last quarter, yet the put/call ratio indicates a bullish outlook for the stock.
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment
UBS has initiated coverage on Viridian Therapeutic (NASDAQ:VRDN) with a Buy rating and a $50 price target, citing the company's promising treatments for Thyroid Eye Disease (TED). The investment bank highlighted both VRDN-001, which is under FDA review and could be approved by mid-2026, and VRDN-003, a subcutaneous program with Phase III data expected in the first half of 2026 as a major catalyst. Other analysts from TD Cowen, Jefferies, and Truist Securities have also reiterated Buy ratings, pointing to the company's strong clinical performance and upcoming milestones.
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment
UBS has initiated coverage on Viridian Therapeutic with a Buy rating and a $50.00 price target, citing the company's progress with its Thyroid Eye Disease (TED) treatments. The investment bank highlights the potential FDA approval of VRDN-001 by mid-2026 and the significant opportunity presented by VRDN-003, with Phase III data expected in the first half of 2026. This positive outlook is further supported by recent news of the FDA granting Priority Review status for Viridian's Biologics License Application for veligrotug.
Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. has outlined a transformational 2026 with key pipeline advancements and commercial preparations. The company's veligrotug BLA for thyroid eye disease (TED) has been accepted for Priority Review with a PDUFA target action date of June 30, 2026, and preparations for a mid-year launch are underway. Additionally, topline Phase 3 results for subcutaneous elegrobart (VRDN-003) are expected in Q1 and Q2 2026, and Viridian has submitted an IND for its half-life extended FcRn-inhibitor, VRDN-008, while also unveiling a new TSHR inhibitor program.
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock
Viridian Therapeutics insider Jennifer Tousignant sold 2,272 shares of the company's stock for $70,795.52 on December 31st. Despite recent strong quarterly earnings that surpassed analyst expectations, analysts still forecast a negative full-year EPS. The company currently holds a "Moderate Buy" consensus rating with an average price target of $41.75.
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN)
Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics Inc (VRDN), sold 2,272 shares of the company on December 31, 2025, leaving her with no shares. This transaction follows a balanced insider trading history for VRDN over the past year, with one insider buy and one sell. The stock, trading at $31.16 with a market cap of $2,928.158 million, is considered a "Possible Value Trap, Think Twice" based on its GF Value of $2,301.78.
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN
Simplify Asset Management Inc. has acquired a new position of 50,000 shares in Viridian Therapeutics (NASDAQ:VRDN) during the third quarter, valued at approximately $1.08 million, representing about 0.06% of the company. Other institutional investors like Commodore Capital LP, Maverick Capital Ltd., and Geode Capital Management LLC also adjusted their stakes. Analysts maintain a "Moderate Buy" consensus rating for Viridian Therapeutics with a target price of $41.75, following a significant revenue beat and smaller-than-expected loss per share in their latest earnings report.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages
Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a "Moderate Buy" consensus rating from thirteen brokerages, with an average 12-month price target of $41.75. The company recently reported better-than-expected quarterly earnings, though it remains unprofitable. Insider and institutional buying activity has increased, with major funds like Fairmount Funds and Wellington Management Group significantly raising their stakes.
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN
Rice Hall James & Associates LLC significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 65.2% in the third quarter, acquiring 336,040 additional shares. This institutional investor now holds 851,663 shares valued at approximately $18.38 million. The increase follows Viridian Therapeutics' strong quarterly results, which surpassed analyst expectations for both EPS and revenue, and a "Moderate Buy" consensus rating from analysts with an average target price of $41.75.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK)
This article details recent analyst ratings for several healthcare companies. Viridian Therapeutics (VRDN) received a "Strong Buy" consensus with a significant upside, while Fortrea Holdings Inc. (FTRE) garnered a "Hold" consensus with a projected downside. Cytokinetics (CYTK) also received a "Strong Buy" consensus from analysts, indicating a substantial potential upside.
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC
Needham & Company LLC has raised its price target for Viridian Therapeutics (NASDAQ:VRDN) to $42.00 from $34.00, maintaining a "buy" rating, indicating a potential upside of 29.35%. This update follows an earnings beat by Viridian, with EPS of ($0.34) versus an estimated ($0.82) and revenue of $70.57 million against an estimated $16.21 million. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $41.75, and recently saw significant insider buying.
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating
William Blair analyst Lachlan Hanbury Brown has reiterated a "Buy" rating for Viridian Therapeutics (VRDN) due to its lead program, veligrotug, becoming de-risked. The FDA's acceptance of the biologics license application, along with priority review and a PDUFA date of June 30, 2026, signals strong regulatory confidence. Robust Phase III data showing significant efficacy in thyroid eye disease and convenience advantages over existing treatments further support the positive outlook, suggesting Viridian's shares are currently undervalued.
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Viridian Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for veligrotug, a treatment for thyroid eye disease (TED), granting it Priority Review. This designation shortens the review timeline to six months, with a PDUFA target action date of June 30, 2026. The Priority Review, along with a prior Breakthrough Therapy Designation, was supported by Phase 3 clinical trial data showing veligrotug's effectiveness in improving and resolving diplopia and rapidly reducing proptosis in TED patients.
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyroid Eye Disease Treatment
Viridian Therapeutics (VRDN) has received FDA priority review for its biologics license application for veligrotug, a treatment for thyroid eye disease, with a target action date of June 30, 2026. The company is preparing for commercial launch in the U.S. and plans to seek European approval in early 2026. Despite a challenging revenue growth and profitability, Viridian shows strong liquidity and low leverage, though its high valuation and Beneish M-Score raise some financial concerns.
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease
Viridian Therapeutics Inc. announced that its Biologics License Application (BLA) for Veligrotug, a treatment for Thyroid Eye Disease, has been accepted for priority review. The PDUFA target action date is set for June 30, 2026, and the company plans to submit a Marketing Authorization Application to the EMA in Q1 2026.
Viridian Therapeutics stock reaches 52-week high at 33.67 USD
Viridian Therapeutics Inc. (VRDN) has reached a new 52-week high, with its stock price hitting $33.67 USD, reflecting an 81% increase over the past year and a 103% surge in the last six months. This strong performance is supported by investor confidence in its therapeutic developments, a favorable analyst consensus, and recent positive news including a Biologics License Application submission for veligrotug and multiple price target increases from analysts. The company's $3.08 billion market cap is trading slightly above its Fair Value, with analysts targeting up to $50.
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx SE announced it is discontinuing its Phase 3 UplighTED studies for efgartigimod subcutaneous treatment for moderate to severe thyroid eye disease (TED) due to futility based on an interim analysis. Although the drug showed a favorable safety profile, the studies did not meet desired outcomes, surprising analysts who expected FcRn inhibition to be effective. This development is seen as positive for the IGF-1R antibody class, particularly benefiting companies like Viridian Therapeutics Inc., whose veligrotug is anticipated to receive FDA approval for TED by 2026, complementing Amgen's Tepezza.
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts
Viridian Therapeutics (VRDN) stock surged on December 15, 2025, driven by positive analyst actions and the discontinuation of a competitor's Phase 3 thyroid eye disease (TED) studies. The company is advancing veligrotug, with a BLA submitted to the FDA, and VRDN-003, with Phase 3 data expected in H1 2026. Viridian attributes its strong financial position to a recent public equity offering and royalty financing, supporting its strategic pipeline and aiming for profitability.
Viridian Therapeutics stock reaches 52-week high at 33.67 USD
Viridian Therapeutics (VRDN) stock has surged by 81% over the past year and 103% over the last six months, reaching a 52-week high of $33.67. This strong performance follows the submission of a Biologics License Application for veligrotug, its thyroid eye disease therapy, and multiple analysts raising their price targets for the company. The biotech firm's market capitalization is $3.08 billion, with analysts setting a high price target of $50.
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx SE announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod in moderate to severe thyroid eye disease due to a futility recommendation from an independent data monitoring committee. This decision is seen as positive for competing IGF-1R antibody treatments, particularly benefiting Viridian Therapeutics Inc., which is expected to receive FDA approval for its TED drug in 2026. Despite the setback, Argenx's shares were down following the announcement, while analysts maintain an Outperform rating for the company due to other strong programs.
Viridian Therapeutics (NASDAQ:VRDN) Builds Targeted Antibody Programs
Viridian Therapeutics (NASDAQ:VRDN) is focused on advancing targeted therapies for serious and rare autoimmune conditions. The company utilizes a precision-focused approach involving research, translational science, and structured clinical development programs. This strategy aims to deliver innovative solutions for patients with unmet medical needs in this specialized field.
Maverick Capital Ltd. Grows Position in Viridian Therapeutics, Inc. $VRDN
Maverick Capital Ltd. increased its stake in Viridian Therapeutics, Inc. by 9.5% in Q2, acquiring 195,736 additional shares, bringing its total to 2,257,010 shares valued at approximately $31.6 million. This comes after Director Fairmount Funds Management LLC also significantly increased its ownership through a $10 million share purchase. The company reported strong Q3 earnings, beating revenue expectations and receiving a largely bullish outlook from analysts with an average price target of around $41.
Evaluating Viridian Therapeutics (VRDN) After William Blair’s New ‘Outperform’ Rating and Rising Investor Optimism
William Blair initiated coverage on Viridian Therapeutics (VRDN) with an "Outperform" rating, contributing to increased investor optimism, reflected in recent stock performance. Despite a high price-to-sales ratio suggesting overvaluation, a discounted cash flow (DCF) model indicates the stock might be significantly undervalued, presenting a mixed picture for potential investors. The article urges investors to consider risks and conduct further research.
Evaluating Viridian Therapeutics (VRDN) After William Blair’s New ‘Outperform’ Rating and Rising Investor Optimism
William Blair has initiated coverage on Viridian Therapeutics (VRDN) with an "Outperform" rating, contributing to growing investor optimism for the biotech company. While the stock has seen significant short-term gains and trades at a high price-to-sales ratio, suggesting overvaluation by traditional metrics, a Discounted Cash Flow (DCF) model indicates it may be significantly undervalued. The article prompts investors to consider if the market is correctly pricing Viridian's future growth potential or if a mispricing exists.
